Pancreatitis: The life-threatening reaction linked to weight loss injections
The medicines regulator is investigating after hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs.
The Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England have launched the Yellow Card Biobank project to examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by people's genetic makeup.
New MHRA data shows that since the drugs were licensed, there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have also been fatal.
The cases reported include:
181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro.
116 reported reactions of this kind linked to liraglutide.
113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy.
101 reported reactions of this kind linked to exenatide.
52 reported reactions of this sort linked to dulaglutide and 11 reported reactions to lixisenatide.
The fatalities reported include:
Five people died following acute and chronic pancreatitis linked to tirzepatide.
One person died following reported reactions of this kind linked to liraglutide.
One person died following reported reactions of this kind linked to semaglutide.
Three people died following reported reactions of this kind linked to exenatide.
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Acute pancreatitis is a condition where the pancreas - a small organ behind the stomach that helps with digestion - becomes inflamed over a short period of time.
While it typically resolves within about a week, some people with severe acute pancreatitis can go on to develop serious complications.
The NHS says the most common symptoms of acute pancreatitis include sudden, severe abdominal pain, feeling or being sick and a fever or high temperature of 38C or more.
Chronic pancreatitis, on the other hand, is when the organ becomes permanently damaged from inflammation, and typically occurs after one or more attacks of acute pancreatitis.
The most common symptom of chronic pancreatitis is repeated episodes of severe abdominal pain, particularly in the middle or left side, which can move along your back. It is described as a burning or shooting pain that comes and goes. However, as the condition progresses, the painful episodes may become more frequent and severe.
Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with diabetes and ongoing nausea and vomiting.
The MHRA is calling for people who are taking GLP-1 medicine and have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
The most common side effects, which may affect more than 1 in 10 patients, are gastrointestinal, including nausea, vomiting, constipation and diarrhoea, according to the MHRA. These are more likely to occur at the start of treatment or after a recent increase in dose.
While manageable, they can sometimes lead to more serious complications such as severe dehydration and kidney damage.
In 2024, the MHRA warned of other serious but less common side effects of GLP-1RAs, including pancreatitis and gall bladder disorders, which may occur in between 1 in 100 and 1 in 10,000 patients.
Hypoglycemia, or low blood sugar, can also occur in non-diabetic patients using some GLP-1RAs for weight management.
Professor Matt Brown, chief scientific officer of Genomics England, said that like all medicines, 'there can be a risk of serious side effects'.
'We believe there is real potential to minimise these, with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Fat jabs taken by millions linked to 560 cases of deadly side effect and 10 deaths
The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed that more than 560 suspected cases of pancreatitis have been linked to GLP-1 drugs. Pancreatitis is inflammation of the pancreas, which can be either acute (sudden and short-term) or chronic (long-term and ongoing). GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are a class of medications primarily used to treat type 2 diabetes and, increasingly, obesity, such as Mounjaro, Wegovy, and Ozempic. Read more: State pension £11,973 warning to anyone turning 65 soon The UK's medicines regulator has said that since the drugs were approved, 181 cases of pancreatitis have been linked to tirzepatide, the active ingredient in Mounjaro. This includes five deaths. Additionally, 13 cases have been linked to semaglutide, found in Wegovy and Ozempic. One death has been linked here. While another jab, Liraglutide, has been tied to 116 suspected cases and one death. Exenatide has been linked to 101 cases, with three deaths. Dulaglutide and Lixisenatide, on the other hand, have been linked with 63 cases. No known deaths have been associated. Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Pancreatitis can also be triggered by gallstones or alcohol. Yet, the MHRA believes there could be a genetic link in some patients, with the regulator launching a new study to investigate its findings further.
Medscape
an hour ago
- Medscape
Promising Weight-Loss Compound Targets Energy Expenditure
A new weight-loss compound targeting energy expenditure rather than appetite suppression showed early efficacy in a first-in-human study. The compound, SANA (MVD1; Eolo Pharma), activates creatine-dependent thermogenesis, a novel approach to obesity and metabolic disease compared to appetite suppression, explained Eolo Pharma CEO María Pía Garat. 'To our knowledge, SANA is the only small molecule in clinical development that targets this mechanism, and we expect growing interest in this pathway as our data progresses.' SANA has completed phase 1a/b trials, demonstrating safety, tolerability, and early efficacy over 15 days of treatment, she told Medscape Medical News . 'If upcoming phase 2 trials replicate these results and support a clear benefit-risk profile, we believe SANA could potentially reach the market within the next 4-5 years, subject to regulatory pathways and ongoing trial outcomes.' The study was published online in Nature Metabolism . 'Complementary Therapeutic Approach' SANA, a nitroalkene derivative of salicylate, demonstrated efficacy in preclinical models of diet-induced obesity and significantly reduced liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue. Unlike glucagon-like peptide 1 (GLP-1) receptor agonists that are associated with muscle wasting and loss of lean mass, SANA was shown in preclinical models to significantly preserve and at times increase lean muscle mass while reducing fat mass. Specifically, EchoMRI analysis in diet-induced obese mice showed that SANA-treated animals had a greater percentage of lean body mass than control animals, despite substantial fat loss. Based on the accumulated preclinical evidence indicating that the compound might be a suitable first-in-class drug for treatment of obesity and comorbidities, the researchers embarked on a double-blind, randomized, placebo-controlled phase 1a/b study. The trial included a single ascending dose (200-800 mg) cohort of 17 lean volunteers and a multiple ascending dose (200-400 mg) cohort of 24 individuals with obesity. The primary endpoint was safety and tolerability. Secondary and exploratory endpoints included pharmacokinetics, tolerability, body weight, and metabolic markers. SANA was shown to be safe and well tolerated at all dose levels, with no serious adverse events reported. In the Phase 1b portion, patients receiving the drug experienced a significant reduction in body weight compared to placebo, along with improvements in fasting glucose and insulin resistance as measured by HOMA-IR. The metabolic improvements were observed after 2 weeks of treatment and occurred without any significant changes in diet or activity levels. 'SANA introduces a novel and potentially complementary therapeutic approach to obesity and metabolic disease — one that doesn't rely on appetite suppression but instead taps into a previously underutilized biological mechanism, namely, creatine-driven thermogenesis,' Garat said. 'It may also offer an alternative for patients who cannot tolerate GLP-1 therapies or who experience undesirable side effects. Additionally, its oral or subcutaneous dosing flexibility could support patient adherence in real-world settings.' That said, she added, 'As with any first-in-human compound, long-term safety, especially with chronic use, will need to be carefully monitored.' The study had limitations. Although the human results support the notion that SANA may be effective in humans, the trial was designed to test safety and tolerability. 'The efficacy of SANA in humans needs to be further studied in a phase 2 clinical trial, with longer treatment, increased sample number, and extended measurements to validate its efficacy and mechanism of action,' the authors wrote. 'As such, the efficacy results presented here, although promising, are still preliminary and subject to further validation.' The authors had various forms of funding, as detailed in the paper. Multiple authors declared holding shares in Eolo USA and/or serving as advisors to the company.
Yahoo
2 hours ago
- Yahoo
Weight loss jabs study begins after reports of pancreas issues
A study into potential serious side effects of weight loss jabs has been launched after hundreds of people reported problems with their pancreas. The Medicines and Healthcare Regulatory Agency (MHRA) and Genomics England are asking people on weight loss drugs who have been hospitalised by acute pancreatitis to get in touch. There have been hundreds of reports of acute and chronic pancreatitis from people who have taken drugs such as Mounjaro, Ozempic and Wegovy, although none are confirmed as being caused by the medicines. The aim is to "better predict those most at risk of adverse reactions", said MHRA chief safety officer Dr Alison Cave. The study is being run through the MHRA's Yellow Card scheme, which allows anyone to report an issue with a medicine, vaccine or medical device to help identify safety issues as early as possible Patients aged 18 and over, with bad reactions to the weight loss jabs - which are also licensed for type 2 diabetes - are being asked to report the detail on the Yellow Card website. They will then be asked if they would be willing to take part in the study, which will check whether some people are at a higher genetic risk of acute pancreatitis when taking these medicines. Patients will be asked to submit more information and a saliva sample, with the overall aim of reducing the occurrence of the side effects in future, says the MHRA. Cases recorded on the Yellow Card website up until 13 May this year include 10 in which patients, who were using weight loss drugs, died from the effects of pancreatitis - but it is not clear whether other factors also played a part. It is impossible to know exactly how many people in the UK are on weight loss drugs as many users obtain them online through unregulated sources, rather than through their doctors. Health officials have suggested the jabs could help turn the tide on obesity. However, they have also warned the drugs are not a silver bullet and often come with side effects, commonly including nausea, constipation and diarrhoea. And the MHRA has also warned that Mounjaro could make the oral contraceptive pill less effective for some patients. Strict rules as GPs start to prescribe weight loss jab Mounjaro How do weight loss drugs like Mounjaro and Wegovy work? Weight-loss drugs tested in head-to-head trial Dr Alison Cave, the MHRA's chief safety officer said information from the study "will help us to better predict those most at risk of adverse reactions, enabling patients across the UK to receive the safest medicine for them, based on their genetic make-up". She said evidence showed almost a third of side effects to medicines could be prevented with genetic testing. "It is predicted that adverse drug reactions could cost the NHS more than £2.2bn a year in hospital stays alone," she added. Prof Matt Brown, chief scientific officer at Genomics England, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. "We believe there is real potential to minimise these, with many adverse reactions having a genetic cause." He said the next step would be to "generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system".
